top of page
Photo of Douglas Grossman, M.D.

Douglas Grossman, M.D.

DERMATOLOGY

Douglas Grossman, MD, PhD, is an investigator in Huntsman Cancer Institute's (HCI) Melanoma Program and a Professor in the Department of Dermatology at the University of Utah School of Medicine. He is Co-Leader of the Melanoma center at HCI. He sees patients at risk for melanoma and non-melanoma skin cancer, with a special interest in patients who have a personal or family history of melanoma; numerous and/or atypical moles (nevi); a personal history of basal or squamous cell carcinoma; or a history of excessive sun exposure. Grossman had directed the Mole Mapping Program at HCI since 2004. Grossman's lab studies mechanisms of tumor development and metastasis in melanoma. In addition, they study the role of UV-induced oxidative stress and DNA damage using human nevi (moles) as a model system. They are using this knowledge to develop novel chemopreventive agents for patients at increased risk for melanoma. Grossman received his MD and PhD from Baylor College of Medicine, completed an internship at Yale-New Haven Hospital, and completed a dermatology residency at Yale. He remained at Yale for a research fellowship in cancer biology, and then joined Huntsman Cancer Institute and the University of Utah School of Medicine faculty in 2001. Douglas Grossman, MD, PhD, is an expert in the early diagnosis and treatment of skin cancers. He received his medical degree from Baylor College of Medicine in 1994, and completed his dermatology training at Yale University School of Medicine in 1998. Following a research fellowship in cancer biology at Yale, he was recruited to the University of Utah in 2001. He sees patients with a personal history of skin cancer or excessive sun exposure, and those at increased risk for melanoma who may have numerous or atypical moles or family members with melanoma. He directs the Mole Mapping Program at the Huntsman Cancer Institute.

See More Experts

FERRIS_LAURA_MD_D_faculty_edited_edited.jpg

Dr. Laura

Ferris

Dermatology

Sancy Leachman, M.D., Ph.D_edited.jpg

Dr. Sancy Leachman

Dermatology

chapman_180515_05_1200x800_edited.jpg

Dr. Paul Chapman

Medical Oncology

12/2022

Interview with Dr. Douglas Grossman, MD

JUMP TO SECTION

youtube-icon-flat-red-play-button-logo-vector.png

01

(0:07 - 1:00)

Introduction

youtube-icon-flat-red-play-button-logo-vector.png

02

(1:01- 5:18)

Dr. Grossman describes his clinical practice. Who are at high risks for developing melanoma?  Who needs mole mapping for monitoring? How to use photos for self exam?

youtube-icon-flat-red-play-button-logo-vector.png

03

(5:18 - 8:20)

What is gene expression profiling (GEP) in managing patients with melanoma? Learn about terms like RNA, DNA, protein expression, and PCR. Does GEP work? What are the cost and pitfalls?

youtube-icon-flat-red-play-button-logo-vector.png

04

(8:21 - 11:34)

What were the reasons for developing the GEP using biopsied specimens to assign risk levels for melanomas? Why do we need this particular GEP testing? Can this particular GEP test improve prognostic predication?

youtube-icon-flat-red-play-button-logo-vector.png

05

(11:34 - 15:37)

How much values does this particular GEP test add to clinical management?  

youtube-icon-flat-red-play-button-logo-vector.png

06

(15:37 - 23:25)

Case study: 0.4mm Breslow thickness.  What is the value of GEP for this patient? What are the downside risks of ordering GEP testing for this patient? What do we do if the GEP test shows high risk? The 5% rule in medicine? What is the cost of the test? 

youtube-icon-flat-red-play-button-logo-vector.png

07

(23:25 - 27:53)

Under what condition will Dr. Grossman consider ordering this particular GEP test? What about the melanoma that is 0.8mm and transacted at the base, will you order GEP for this patient? Immediate application to predict positive sentinel lymph node. What is the role of GEP testing in the current NCCN guidelines?

youtube-icon-flat-red-play-button-logo-vector.png

08

(27:53 - 32:50)

 Dermtech Inc technology’s GEP testing to diagnose melanoma in vivo and in a non-invasive fashion. What are the advantages and limitations?

youtube-icon-flat-red-play-button-logo-vector.png

09

(32:50 - 33:22)

Conclusion

bottom of page